Risk Factors for Cognitive Impairment in Patient with Parkinson's Disease Treated with Levodopa.
10.24304/kjcp.2018.28.4.285
- Author:
Kyung Sook KIM
1
;
Kyung Eun LEE
;
Myung Koo LEE
Author Information
1. Department of Clinical Pharmacy, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea.
- Publication Type:Original Article
- Keywords:
Parkinson disease;
levodopa;
cognitive dysfunction;
dementia
- MeSH:
Age of Onset;
Cognition;
Cognition Disorders*;
Comorbidity;
Dementia;
Hallucinations;
Humans;
Levodopa*;
Mood Disorders;
Parkinson Disease*;
Retrospective Studies;
Risk Factors*;
Sleep Initiation and Maintenance Disorders
- From:Korean Journal of Clinical Pharmacy
2018;28(4):285-292
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Long-term levodopa therapy relieves the motor dysfunction associated with Parkinson's disease (PD), but has various effects on non-motor symptoms, including cognitive dysfunction, hallucinations, and affective disorders, and can exacerbate certain aspects of dementia-like cognitive dysfunction. Here, we investigated the relationship between levodopa treatment and development of dementia in patients with PD. METHODS: This retrospective study analyzed 76 consecutive patients with PD who had taken levodopa between 2011 and 2015. The participants were initially free of dementia and had initial daily levodopa doses of below 600 mg. Patients who did and did not develop comorbid dementia were compared in terms of potential predictor variables, including PD onset age, sex, levodopa doses, and non-dementia comorbidities. RESULTS: Of the 76 patients, 21 (27.6%) developed dementia, which was followed by hallucinations and insomnia. The independent predictors of incident dementia were PD onset age and second-year and third-year average levodopa doses that were higher than the first-year average levodopa dose. Patients who developed dementia had significantly higher average daily levodopa doses and levodopa dose increases over the 6-year treatment period than those who did not develop dementia. In addition, patients with higher levodopa doses were more likely to experience hallucinations. CONCLUSION: These results suggest that increases in levodopa doses may be associated with a greater risk of cognitive impairment in patients with PD. Therefore, motor and cognitive functions and levodopa dose increases should be evaluated regularly during long-term levodopa therapy in patients with PD.
